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Background: Posttraumatic stress disorder (PTSD) is associated with an enhanced risk for cardiovascular and other
inflammatory diseases. Chronic low-level inflammation has been suggested as a potential mechanism linking these
conditions.
Methods: We investigated plasma cytokine levels as well as spontaneous and lipopolysaccharide (LPS)-stimulated
cytokine production by peripheral blood mononuclear cells (PBMCs) in a group of 35 severely traumatized PTSD
patients compared to 25 healthy controls.
Results: Spontaneous production of interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α by isolated PBMCs
was significantly higher in the PTSD compared to the control group and even correlated with PTSD symptom
severity within the PTSD group. In contrast, circulating plasma levels of pro- and anti-inflammatory cytokines such
as IL-6, IL-8, IL-10, TNF-α, or monocyte chemotactic protein (MCP)-1 were not significantly altered in PTSD patients
compared to healthy controls.
Conclusions: Our findings indicate that PBMCs of PTSD patients are already pre-activated in vivo, providing further
evidence for low-grade inflammation in PTSD. This might possibly represent one psychobiological pathway from
PTSD to poor physical health.
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InflammationBackground
Repeated exposure to traumatic events such as rape,
combat or natural disasters has dramatic effects on men-
tal health [1-3]. Frequent symptoms in the aftermath of
such events include repetitive intrusive recollections of
the trauma, persistent avoidance of trauma reminders,
emotional numbing and hyperarousal – the core symp-
toms of posttraumatic stress disorder PTSD [4].* Correspondence: Iris.Kolassa@uni-ulm.de
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reproduction in any medium, provided the orIn addition to psychiatric morbidity, numerous studies
have shown that traumatic stress and especially PTSD
are associated with poor self-reported physical health,
increased utilization of medical services, and an elevated
risk for multiple comorbid medical disorders such as re-
spiratory, gastrointestinal, musculoskeletal, inflammatory
and autoimmune diseases [5-7]. In particular, it has been
found that cardiovascular disease and its risk factors are
more prevalent among individuals with PTSD [5,6,8],
with two recent studies even demonstrating a prospect-
ive relationship between PTSD symptoms and coronary
heart disease [9] or PTSD and cardiovascular mortality,
respectively [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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such as smoking, alcohol abuse or low physical activity
[11], chronic low-level inflammation has been discussed as
a potential mechanism linking cardiovascular disease to
PTSD [12]. This argumentation is supported by epidemio-
logical and clinical studies demonstrating a strong and
consistent relationship between markers of inflammation
and risk of future cardiovascular events [13,14].
However, studies investigating pro-inflammatory mar-
kers in PTSD patients have yielded mixed results. Some
studies reported higher levels of IL-1β [15,16], IL-6 [17],
and TNF-α [12] in the plasma or elevated levels of IL-6 in
the cerebrospinal fluid [18] of PTSD patients compared to
control subjects. Furthermore, Spitzer et al. [19] found
that, in a sample of 3049 adults, PTSD positive partici-
pants had significantly higher odds for elevated levels of
C-reactive protein (CRP) than those without PTSD. In
contrast, other studies did not find significant group dif-
ferences with respect to circulating levels of IL-1β [12],
IL-6 [12,20], and CRP [12] or even reported lower levels
of CRP [21] and IL-8 [20] in PTSD patients.
Likewise, ambiguous results have been obtained by
studies investigating the production of pro-inflammatory
cytokines in whole blood following ex vivo stimulation
with lipopolysaccharide (LPS) and/or phytohemagglu-
tinin (PHA). Whereas some studies reported higher
LPS-stimulated IL-6 production [22] or increased LPS/
PHA-induced production of IL-6 and TNF-α [23] in indi-
viduals with PTSD, other studies showed no group differ-
ences with respect to PHA-induced interferon (IFN)-γ
[24] or LPS-induced TNF-α production [22]. One study
by de Kloet et al. [24] even reported decreased TNF-α
production in LPS-stimulated whole blood of PTSD
patients compared to controls.
These inconsistent findings might partly be explained
by variations in sample characteristics, such as differ-
ences with respect to the type of traumata experienced
(e.g. childhood vs. adulthood trauma), time elapsed since
the traumata (e.g. populations studied shortly after trau-
matic experiences or during ongoing threat vs. patients
with chronic symptoms), comorbidities, and differences
with respect to PTSD symptom severity (mild symptoms
after a single trauma in comparison to severe symptoms
after experiencing multiple traumata), as well as varying
sample sizes. In particular studies investigating plasma
cytokine levels consisted mostly of small patient groups,
making the results error-prone.
Here we investigated plasma levels of pro- and anti-
inflammatory cytokines in a well-defined group of 35 se-
verely affected PTSD patients with war and torture
experiences mainly experienced during late adolescence
and adulthood and a chronic disease pattern, compared
to 25 healthy ethnically matched control subjects. For a
subsample of 16 PTSD patients and 18 control subjects,we additionally analyzed 1) LPS-stimulated production
of IL-1β, IL-6 and TNF-α by peripheral blood mono-
nuclear cells (PBMCs), as well as 2.) spontaneous cyto-




We analyzed 35 individuals with current PTSD (19 male,
16 female; mean age = 32.6, range 16–51) according to
the DSM-IV [4] and 25 healthy control subjects (8 male,
17 female; mean age = 26.8 years, range 18–45). PTSD
patients were refugees, with chronic (mean symptom
duration = 7.6 years, SD = 4.6) and severe (mean sum
score in the Clinician Administered PTSD Scale, CAPS
[25] = 80.0, SD = 17.5) forms of PTSD due to multiple
highly stressful war and torture experiences, mainly
experienced during late adolescence and adulthood. In
addition to the PTSD diagnosis, 27 patients met the DSM-
IV criteria for a current major depressive episode. Thirteen
PTSD patients reported current intake of hypnotic, anxio-
lytic, antidepressant or neuroleptic medication and one
woman reported the use of oral contraceptives. Thirty-
seven percent of the PTSD patients were smokers (for
subjects’ characteristics see Table 1). All patients were
recruited from the Psychotrauma Research and Outpatient
Clinic for Refugees, University of Konstanz, Germany. The
healthy control group was recruited through advertise-
ment and was comparable to the patient group with re-
gard to region of origin. Except for four women reporting
the intake of oral contraceptives, all control subjects were
free of medication. Sixteen percent of the control subjects
were smokers (see Table 1).
Exclusion criteria for the study were intake of gluco-
corticoids or acute (1 PTSD patient and 2 controls) and
chronic (1 PTSD patient and 3 controls) somatic ill-
nesses. In addition, control subjects were excluded if
they met the criteria for any mental disorder according
to DSM-IV (n = 4), or reported intake of psychotropic
medication (n = 2). PTSD patients were excluded if they
met the criteria for comorbid alcohol or substance abuse
and dependence (n = 3) or a current or past history of a
psychosis (n = 1) according to DSM-IV. Furthermore,
participants were screened for possible HIV and hepatitis
A, B and C infections. All samples were negative for HIV
or hepatitis C. Subjects classified with acute or chronic
hepatitis A or B (3 PTSD patients and 3 controls) were
excluded from the study, reducing the initially enrolled
sample of 44 individuals with PTSD and 39 controls to 35
PTSD patients and 25 control participants.
Basal plasma cytokine measurements were obtained
from all subjects (PTSD, n = 35; healthy controls, n = 25).
Spontaneous and LPS-induced cytokine production by
cultured PBMCs was investigated in a subsample of 16
Table 1 Sociodemographic and clinical characteristics of
PTSD patients and controls
Variables PTSD Controls p
(n = 35) (n = 25)
Agea (y) 32.6 ± 9.1 29.1 ± 9.7 .01
Sex (f/m) 16/19 17/8 .09
Region of Origin (%) .06
Africa 20.0% 8.0%
Balkan 17.2% 48.0%
Middle East 62.8% 44.0%
Smokers (%) 37.1% 16.0% .07





Contraceptives (%) 2.8% 16.0% .10
Comorbid depression (%) 77.1% 0% <.0005
Number of traumatic event typesa
War or torture events 10.8 ± 5.4 2.3 ± 5.0 <.0005
CAPS events 6.9 ± 2.1 3.4 ± 2.0 <.0005
CAPS Scorea 80.0 ± 17.5 5.4 ± 11.2 <.0005
HAMD Scorea 26.1 ± 8.2 4.1 ± 5.6 <.0005
SOMS Scorea 28.7 ± 12.4 5.5 ± 8.5 <.0005
aData are presented as mean ± SD.
*For pair-wise group comparisons of continuous variables, we performed
t-tests, differences of categorical variables were evaluated by applying χ2 tests
for independence. (Y) = years; (f) = female; (m) =male; CAPS, Clinician
Administered PTSD Scale; HAM-D, Hamilton Depression Rating Scale; SOMS-7,
Screening for Somatoform Symptoms-7.
Table 2 Sociodemographic and clinical characteristics of
the subgroup of PTSD patients and control subjects for
which we analyzed cytokine production by PBMCs
Variables PTSD Controls p
(n = 16) (n = 18)
Agea (y) 36.1 ± 9.5 26.7 ± 7.4 .003
Sex (f/m) 7/9 11/7 .31
Region of Origin (%) .16
Africa 18.7% 5.6%
Balkan 25.0% 55.5%
Middle East 65.3% 38.9%
Smokers (%) 37.5% 16.7% .17





Contraceptives (%) 0% 16.7% .23
Comorbid depression (%) 75.0% 0% <.0005
Number of traumatic event typesa
War or torture events 11.0 ± 5.8 1.8 ± 3.9 <.0005
CAPS events 7.2 ± 1.7 3.3 ± 1.9 <.0005
CAPS Scorea 82.5 ± 16.5 7.0 ± 12.8 <.0005
HAMD Scorea 25.2 ± 8.1 4.6 ± 6.3 <.0005
SOMS Scorea 28.4 ± 13.8 4.9 ± 8.2 <.0005
aData are presented as mean ± SD.
*For pair-wise group comparisons of continuous variables, we performed
t-tests, differences of categorical variables were evaluated by applying χ2 tests
for independence. (Y) = years; (f) = female; (m) =male; CAPS, Clinician
Administered PTSD Scale; HAM-D, Hamilton Depression Rating Scale; SOMS-7,
Screening for Somatoform Symptoms-7.
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the respective subject characteristics).
Procedure
All participants underwent an extensive standardized
clinical interview administered by experienced clinical
psychologists and trained translators, starting always at
10:00 a.m.: Upon arrival at the outpatient clinic, proce-
dures were explained to the participants and written
informed consent was obtained. Subsequently, blood (t1)
for white blood cell (WBC) differential counts, plasma
cytokines, and PBMC isolation was drawn. Afterwards,
sociodemographic information as well as medical infor-
mation was acquired. Somatic symptoms were assessed
using a shortened version of Screening for Somatoform
Symptoms-7 SOMS-7, [26]. During the second part of the
interview, participants were interviewed in a standardized
manner about their individual traumatic experiences using
the event checklist of the CAPS [25] and the vivo checklist
of war, detention and torture events [27], which assesses
common traumatic experiences in conflict regions andduring torture. Subsequently, PTSD symptom frequency
and severity were assessed with the CAPS [25]. Finally, the
Mini International Neuropsychiatric Interview M.I.N.I.,
[28] was applied to screen for potential comorbid mental
disorders. In addition, depressive symptoms were assessed
with the Hamilton Depression Rating Scale HAM-D, [29].
One week after the standardized clinical interview the par-
ticipants were invited for a second time. Again, blood
samples for plasma cytokines were collected at 10:00 am
(t2), to test for the stability of basal (t1) cytokine levels.
All procedures were approved by the Ethics Commit-
tee of the University of Konstanz and were carried out
in accordance with the Declaration of Helsinki 2008.WBC differential count
Absolute numbers of leukocytes, lymphocytes, neutrophils,
monocytes, eosinophils, and basophils were obtained using
an automated hematology analyzer (XT-2000i, Sysmex,
Horgen, Switzerland).
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Peripheral blood mononuclear cells (PBMCs) were iso-
lated from citrated blood by density gradient centrifuga-
tion using commercially available cell preparation tubes
(VacutainerW CPT™ Cell Preparation Tube, BD Bios-
ciences, Franklin Lakes, NY, USA) according to the manu-
facturer’s instructions. Freshly isolated PBMCs (2 × 105)
were suspended in 200 μl RPMI 1640 containing 10% fetal
bovine serum and were cultured for 24 h in 96-well flat-
bottom culture plates in presence or absence of 1 μg/ml
lipopolysaccharide (LPS) from Salmonella abortus equi
(Sigma-Aldrich, Taufkirchen, Germany).
Cytokine analysis
Cytokine levels in plasma and culture supernatants were
quantified using multiplex bead-based assays (Bio-Plex
Cytokine Assays, Bio-Rad Laboratories, Hercules, CA,
USA). Samples were prepared according to the manufac-
turer’s instructions and were analyzed in triplicate on a
dual-laser flow cytometer equipped with high through-
put sampler (LSR II, BD Immunocytometry Systems,
San Jose, CA, USA). Absolute cytokine levels were cal-
culated based on the mean fluorescence intensity of
cytokine standards. Detection limits of the assays,
defined as the mean of background value plus 3 SD,
were 0.07 pg/ml (IL-6), 0.75 pg/ml (IL-8), 0.14 pg/ml
(IL-10), 0.24 pg/ml (TNF-α), and 0.38 pg/ml (MCP-1),
respectively.
Statistical analyses
Data analysis was performed using R 2.15.2 [30]. Group
comparisons with respect to sociodemographic and clin-
ical variables were performed using chi-square tests for
categorical data and t-tests for continuous data. Basal
plasma and LPS-stimulated cytokine levels were ana-
lyzed using ANOVAs with group (PTSD patients vs.
controls) as independent variable. Since some of the im-
munological variables did not met requirements for
parametric testing (normality of residuals), statistical sig-
nificance for the immune measures was assessed by non-
parametric permutation tests. In each case, the full
model and a reduced model omitting the factor(s) of
interest were fitted and the statistic of interest (usually
an F statistic) was calculated. Next, residuals under the
reduced model were randomly permuted 10,000 times.
In each case, the randomly permuted residuals were
added back to the (non-permuted) fitted values under
the reduced model. The resulting randomized dependent
values were then again used in fitting full and reduced
models, yielding a “permutation” statistic. The p values
reported below are given by the position of the original
statistic in the empirical distribution of the permutation
statistic [31,32]. In each case, we also investigated gender
as well as smoking status as a covariate. We also wantedto control for the age difference between groups. How-
ever, as both groups differed significantly in age, the pre-
conditions for calculating and interpreting an Analysis
of Covariance were not fulfilled [33,34]. In order to
nevertheless understand our data better, we calculated
Spearman correlations between age and dependent vari-
ables separately for the PTSD and control group.
Reported p values represent exact p values. In addition,
we report p values corrected for multiple comparisons
with Holm’s stepwise procedure [35], applied first for the
five cytokines measured in plasma and then for the three
cytokines produced by PBMCs measured in presence or
absence of LPS. Correlations were computed using Spear-
man’s rank correlation coefficient.
Results
Basal plasma cytokine levels
Basal plasma cytokine levels (t1) were generally low in
both PTSD patients and controls. For TNF-α (74.6%)
and IL-10 (44%), a high percentage of samples were
below detection limit (BDL). Better detection rates were
achieved for IL-6 (23.7% BDL), IL-8 (1.7% BDL), and
MCP-1 (5.1% BDL). PTSD patients and control indivi-
duals did not differ with respect to basal plasma levels of
IL-6, IL-10, TNF-α, or MCP-1; this remained true when
including sex or smoking as a covariate. However, IL-8
plasma levels were significantly lower in individuals with
PTSD compared to healthy control subjects (Table 3).
The difference remained significant even when sex or
smoking was included as a covariate, however, after cor-
rection for multiple comparisons it lost significance. For
the measurements repeated after a one-week interval (t2),
we received the same result pattern, except that the group
difference for IL-8 levels was reduced to a trend [PTSD:
25% quantile 3.85, median 5.5, 75% quantile 9.08; Con-
trols: 25% quantile 5.29, median 9.16, 75% quantile 12.71;
F = 2.53, p = .08]. Nonparametric correlation analyses
revealed that plasma levels for t1 and t2 were significantly
related in both control and PTSD groups for IL-6
(PTSD: r = .85, p < .0001; controls: r = .61, p = .002), IL-8
(PTSD: = .76, p < .0001; controls: = .76, p < .0001), IL-10
(PTSD: r= .92, p < .0001; controls: r= .90, p < .0001), TNF-α
(PTSD: r = .78, p < .0001; controls: r = .62, p = .002)
and MCP-1 (PTSD: r = .89, p < .0001; controls: r = .74,
p < .0001), even after controlling for multiple comparisons.
Cytokine production by PBMCs
Blood leukocyte distribution did not differ between PTSD
patients and control individuals (Table 3), nor did it when
including sex or smoking as covariates. However, isolated
PBMCs from PTSD patients spontaneously produced sig-
nificantly higher amounts of IL-1β (F = 11.31, p = .0003),
IL-6 (F= 7.27, p = .005) and TNF-α (F = 5.01, p = .02) than
PBMCs from controls (Figure 1A-C). The group differences
Table 3 Absolute numbers (cells/μl) of leukocyte subpopulations and plasma cytokine levels (pg/ml) in PTSD patients
versus healthy controls
PTSD Controls
Parameter 25% Quantile Median 75% Quantile 25% Quantile Median 75% Quantile F p
Leukocytes 5350 5820 6940 4927.5 5705 6477.5 .84 .38
Lymphocytes 1795.21 2012.1 2352.59 1611.84 1789.82 2102.555 1.77 .19
Neutrophils 2696.68 3265.82 3865.63 2696.17 2990.00 3798.70 .28 .63
Monocytes 409.74 481.28 541.13 370.13 430.44 536.72 .32 .59
Eosinophils 114.95 168.33 225.83 70.92 100.06 181.63 2.55 .12
Basophils 18.02 22.0 30.1 17.40 21.05 30.08 .09 .77
IL-6 0.2 0.5 0.9 0.07 0.35 0.73 .13 .72
IL-8 3.2 5.2 10.4 5.2 8.6 15.9 4.8 .03#
IL-10 0.08 0.20 0.35 0.06 0.20 1.52 2.7 .08
TNF-α 0.19 0.21 0.24 0.21 0.24 0.44 1.1 .37
MCP-1 1.15 2.00 4.05 0.83 2.30 5.95 .06 .82
* Statistical significance for differences in means of immune parameters was assessed by nonparametric permutation tests, using 10,000 random permutations of
residuals under the reduced model.
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Figure 1 Unstimulated spontaneous and LPS-stimulated IL-1β (A), IL-6 (B), and TNF-α (C) production by PBMCs in PTSD patients
compared to controls. The figure shows raw data, jittered horizontally to avoid overlapping points. Horizontal lines indicate means. Statistical
significance for the difference in means of immune parameters was assessed by nonparametric permutation tests, using 10 000 random
permutations of group labels (* p < .05, ** p < .01, *** p < .001).
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after correction for multiple comparisons. Furthermore,
the findings on IL-1β and IL-6 remained when including
sex or smoking as covariates, while the result for TNF-α
was reduced to a trend when including smoking (F = 3.58,
p = 0.06). In addition, nonparametric correlation analyses
within the PTSD group revealed that PTSD symptom se-
verity was positively correlated with the spontaneous pro-
duction of IL-6 (r = .56, p = .02), and TNF-α (r = .58,
p = .02), while the correlation between IL-1β and PTSD
symptom severity was a trend (r = .47, p = .07). Further-
more, LPS-induced IL-6 production was significantly
higher in the PTSD compared to the control group
(F = 7.12, p = .01). The difference remained significant
when correcting for multiple comparisons or when includ-
ing sex or smoking in the model. In contrast, we could not
find group differences in IL-1β and TNF-α production in
LPS-stimulated PBMCs (Figure 1A-C); these latter results
remained true when including sex or smoking in the ana-
lysis. To evaluate the net effect of LPS-stimulation, we fur-
ther calculated the difference in cytokine production
between LPS- and non-stimulated samples, but no group
differences could be detected for IL-1β [PTSD: 25% quan-
tile 1592, median 2903, 75% quantile 4339; Controls: 25%
quantile 1356, median 3409; 75% quantile 5024; F = .35,
p = .56], IL-6 [PTSD: 25% quantile 247, median 1053, 75%
quantile 2730; Controls 25% quantile 1170, median 1461,
75% quantile 2380; F = .03, p = .87], and TNF-α [PTSD:
25% quantile 1006, median 1815, 75% quantile 3264; Con-
trols: 25% quantile 1291, median 1938, 75% quantile 3333;
F = .05, p = .84], which remained true when including sex
or smoking as covariates.
Correlations with age
Spearman correlations between age on the one hand and
plasma IL-6, IL-8, IL-10, TNF-α and MCP-1 at t1 as well
as unstimulated and LPS-induced IL-1β, IL-6 and TNF-α
production by PBMCs, in each case separately for PTSD
patients and control participants, were calculated. None
of the correlations were significant.
Discussion
In the present study we investigated plasma levels of IL-
6, IL-8, IL-10, TNF-α and MCP-1 as well as spontaneous
and LPS-stimulated production of IL-1β, IL-6 and TNF-
α by PBMCs from a group of severely affected PTSD
patients compared to healthy control subjects.
While basal plasma concentrations of pro- and anti-
inflammatory cytokines did not differ significantly in
PTSD patients and controls, we found evidence for a
heightened inflammatory state in PTSD patients when
analyzing spontaneous ex vivo cytokine production. Con-
centrations of IL-1β, IL-6, and TNF-α in supernatants of
unstimulated PBMCs were significantly higher in thePTSD compared to the control group. In addition, correl-
ation analyses within the PTSD group revealed that levels
of IL-6 and TNF-α were significantly related to the sever-
ity of PTSD symptoms as assessed with the CAPS; IL-1β
was also positively associated, but significance was only at
the level of a trend. The group differences reported above
were not ascribable to differences in blood leukocyte dis-
tribution since lymphocyte and monocyte counts were
comparable in both groups. Following the introduction of
smoking as covariate to the model, the finding on TNF-α
was reduced to a trend. The finding of an increased spon-
taneous production of pro-inflammatory cytokines in the
PTSD patients group suggests that PBMCs of PTSD
patients are already pre-activated in vivo. Furthermore, as
in previous studies [22,23], LPS-stimulated PBMCs from
PTSD patients exhibited significantly higher IL-6 secretion
compared to PBMCs from control subjects. However,
when calculating the difference between LPS-stimulated
and non-stimulated cytokine production to evaluate the
net effect of LPS stimulation, no group differences were
found, suggesting that the effect reported above mainly
results from the enhanced spontaneous IL-6 secretion by
PBMCs of PTSD patients. Our finding of a heightened
spontaneous production of pro-inflammatory cytokines in
the PTSD patient group is in agreement with reports that
parameters normally suppressing inflammation are reduced
in PTSD patients. For example, studies have reported lower
cortisol levels [36] and a lower percentage of regulatory T
cells [37] in those with PTSD, which are both crucial
players in controlling inflammation thereby limiting
immunopathological side effects of inflammatory processes
[38,39]. Consequently our results provide further evidence
for a link between PTSD and low-grade inflammation, pos-
sibly representing one psychobiological pathway from
PTSD to inflammatory diseases such as arteriosclerosis
and its clinical manifestations, e.g., myocardial infarction,
stroke, and peripheral vascular disease, often observed in
patients with PTSD [5,8]. Whereas arteriosclerosis has
been formerly considered a simple lipid storage disease,
current evidence supports a fundamental role for inflam-
mation in mediating all stages of this disease. Inflammatory
processes not only promote early atherogenesis and the
progression of lesions, but also contribute decisively to
precipitating acute thrombotic complications of atheroma.
In addition, clinical studies affirm a correlation of circulat-
ing markers of inflammation with propensity to develop is-
chemic events and with prognosis after acute coronary
syndromes [13,14].
Conclusion
In conclusion, repeated exposure to traumatic events
over the lifetime seems to induce long-lasting changes in
the regulation of inflammatory processes that constitute
a form of biological memory of the stressor and might
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to the development of various physical diseases. How-
ever, the interpretation of our results is faced with several
limitations of our study: 1) Groups differed significantly
with respect to age. Unfortunately, correcting for age is
only possible if groups do not differ in this variable see
[33,34]. But as a) spontaneous production of IL-1β, IL-6,
and TNF-α was not significantly correlated with age, nei-
ther for controls nor for PTSD subjects and b) it was posi-
tively related to PTSD symptom severity within the PTSD
group, older age in the PTSD group should not have
accounted for the effects reported above 2) One third of
the PTSD patients took psychotropic medication. 3) We
did not control for the confounding effects of physical ac-
tivity on the immune outcomes. Moreover, as earlier stud-
ies suggest, a heightened inflammatory state does not
seem to hold true for all studied populations of PTSD
patients [20,21,24]. Future studies should therefore investi-
gate whether a heightened inflammatory profile is asso-
ciated with a specific characteristic of PTSD, e.g., whether
it can only be found in PTSD patients with chronic and
severe symptoms or is modulated by the type of trauma
experienced. Eventually, such findings could be the basis
for the development of new trauma treatment approaches,
paying more attention to the potential for improving phys-
ical, in addition to mental health.
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